BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37199687)

  • 1. Degree of crypt atypia correlates with progression to high-grade dysplasia/adenocarcinoma in non-dysplastic Barrett's oesophagus.
    Odze R; Frei N; Khoshiwal AM; Duits LC; Bergman J; Stachler MD
    Histopathology; 2023 Sep; 83(3):406-413. PubMed ID: 37199687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of Crypt Atypia in Barrett's Esophagus: A Clinical, Molecular, and Outcome Study.
    Wang HH; Patil DT; Paulson TG; Grady WM; Odze RD
    Clin Gastroenterol Hepatol; 2024 Apr; 22(4):741-748.e2. PubMed ID: 37879518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus.
    Critchley-Thorne RJ; Davison JM; Prichard JW; Reese LM; Zhang Y; Repa K; Li J; Diehl DL; Jhala NC; Ginsberg GG; DeMarshall M; Foxwell T; Jobe BA; Zaidi AH; Duits LC; Bergman JJ; Rustgi A; Falk GW
    Cancer Epidemiol Biomarkers Prev; 2017 Feb; 26(2):240-248. PubMed ID: 27729357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett's esophagus cohort.
    Lomo LC; Blount PL; Sanchez CA; Li X; Galipeau PC; Cowan DS; Ayub K; Rabinovitch PS; Reid BJ; Odze RD
    Am J Surg Pathol; 2006 Apr; 30(4):423-35. PubMed ID: 16625087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
    Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
    Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crypt dysplasia in Barrett's oesophagus shows clonal identity between crypt and surface cells.
    Khan S; McDonald SA; Wright NA; Graham TA; Odze RD; Rodriguez-Justo M; Zeki S
    J Pathol; 2013 Sep; 231(1):98-104. PubMed ID: 23695891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma.
    Stachler MD; Camarda ND; Deitrick C; Kim A; Agoston AT; Odze RD; Hornick JL; Nag A; Thorner AR; Ducar M; Noffsinger A; Lash RH; Redston M; Carter SL; Davison JM; Bass AJ
    Gastroenterology; 2018 Jul; 155(1):156-167. PubMed ID: 29608884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and grading of dysplasia in Barrett's oesophagus.
    Odze RD
    J Clin Pathol; 2006 Oct; 59(10):1029-38. PubMed ID: 17021130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus.
    Srivastava A; Hornick JL; Li X; Blount PL; Sanchez CA; Cowan DS; Ayub K; Maley CC; Reid BJ; Odze RD
    Am J Gastroenterol; 2007 Mar; 102(3):483-93; quiz 694. PubMed ID: 17338734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.
    Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent confirmed low-grade dysplasia in Barrett's esophagus is a risk factor for progression to high-grade dysplasia and adenocarcinoma in a US Veterans cohort.
    Song KY; Henn AJ; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ
    Dis Esophagus; 2020 Mar; 33(2):. PubMed ID: 31274147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression from low-grade dysplasia to malignancy in patients with Barrett's esophagus diagnosed by two or more pathologists.
    Moole H; Patel J; Ahmed Z; Duvvuri A; Vennelaganti S; Moole V; Dharmapuri S; Boddireddy R; Yedama P; Bondalapati N; Uppu A; Vennelaganti P; Puli S
    World J Gastroenterol; 2016 Oct; 22(39):8831-8843. PubMed ID: 27818599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yield of Repeat Endoscopy in Barrett's Esophagus with No Dysplasia and Low-Grade Dysplasia: A Population-Based Study.
    Visrodia K; Iyer PG; Schleck CD; Zinsmeister AR; Katzka DA
    Dig Dis Sci; 2016 Jan; 61(1):158-67. PubMed ID: 25956705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
    Weston AP; Badr AS; Hassanein RS
    Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia.
    Duits LC; van der Wel MJ; Cotton CC; Phoa KN; Ten Kate FJW; Seldenrijk CA; Offerhaus GJA; Visser M; Meijer SL; Mallant-Hent RC; Krishnadath KK; Pouw RE; Tijssen JGP; Shaheen NJ; Bergman JJGHM
    Gastroenterology; 2017 Apr; 152(5):993-1001.e1. PubMed ID: 28012849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study.
    Verbeek RE; van Oijen MG; ten Kate FJ; Vleggaar FP; Schipper ME; Casparie MK; van Baal JW; Siersema PD
    Am J Gastroenterol; 2012 Apr; 107(4):534-42. PubMed ID: 22270082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA ploidy abnormalities in basal and superficial regions of the crypts in Barrett's esophagus and associated neoplastic lesions.
    Zhang X; Huang Q; Goyal RK; Odze RD
    Am J Surg Pathol; 2008 Sep; 32(9):1327-35. PubMed ID: 18670357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Not all low grade dysplasia in Barrett's oesophagus is the same: using specific histological criteria in predicting progression to neoplasia.
    Tsoi EH; Williams RA; Christie M; Machet D; Deb S; Sundararajan V; Cameron GR; Desmond PV; Taylor ACF
    Pathology; 2021 Oct; 53(6):700-704. PubMed ID: 34420794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.